OS Therapies advanced key clinical, regulatory, and commercial milestones in 3Q25 as it moves closer to bringing OST-HER2 to patients with recurrent, fully resected, pulmonary metastatic osteosarcoma. Final 2-year OS data from the 41-patient Phase 2b trial showed a 2-year OS rate of 75% for OSTHER2 vs 40% in historical controls, with 100% 2-year survival among patients event-free at 12 months, reinforcing durable benefit. Building on a successful End-of-Phase 2 interaction, management is preparing harmonized U.S./ex-U.S. filings with UK MHRA and FDA submissions expected around year-end, supported by its Eversana partnership and a launch plan that anticipates initial PRV monetization in 2026 and commercial OST-HER2 revenues beginning in early 2027. Subsequent to quarter-end, the Company also announced its intent to spin off OS Animal Health (OSAH) into a separately financed, standalone public company in 1H26, with OSTX shareholders expected to receive direct equity participation in the new listing.